Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2008 | 2 |
2009 | 1 |
2010 | 2 |
2011 | 1 |
2013 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Clin Gastroenterol Hepatol. 2013 Aug;11(8):1028-35.e1-2. doi: 10.1016/j.cgh.2013.03.012. Epub 2013 Mar 28.
Clin Gastroenterol Hepatol. 2013.
PMID: 23542331
Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease.
Weiss KH, Gotthardt DN, Klemm D, Merle U, Ferenci-Foerster D, Schaefer M, Ferenci P, Stremmel W.
Weiss KH, et al. Among authors: ferenci foerster d.
Gastroenterology. 2011 Apr;140(4):1189-1198.e1. doi: 10.1053/j.gastro.2010.12.034. Epub 2010 Dec 24.
Gastroenterology. 2011.
PMID: 21185835
Item in Clipboard
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group.
Ferenci P, et al.
Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27.
Gastroenterology. 2008.
PMID: 18503773
Clinical Trial.
Item in Clipboard
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K; Austrian Hepatitis Study Group.
Ferenci P, et al.
Hepatology. 2008 Jun;47(6):1816-23. doi: 10.1002/hep.22262.
Hepatology. 2008.
PMID: 18454510
Clinical Trial.
Item in Clipboard
Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group.
Ferenci P, et al.
Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. doi: 10.1053/j.gastro.2009.10.058. Epub 2009 Nov 10.
Gastroenterology. 2010.
PMID: 19909752
Clinical Trial.
Item in Clipboard
Cite
Cite